Investors

Press Releases

Press releases issued by Palatin are accessible below. These press releases contain additional information about our business, clinical trial developments, research and development activities, financial achievements, and strategic partnerships.

Select Year
Search …

Found 348 Results

Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update

November 13, 2025

Palatin Technologies Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwriters’ Over-Allotment Option

November 12, 2025

Palatin Presents Data at ObesityWeek® 2025 Highlighting Promise of Melanocortin-Based Therapies for Obesity

November 6, 2025

Palatin Technologies Announces Pricing of Upsized $15.8 Million Public Offering

November 6, 2025

Palatin Earns €5.5 Million ($6.5 Million) Milestone Payment in Retinal Disease Collaboration with Boehringer Ingelheim

September 22, 2025

Boehringer Ingelheim and Palatin Technologies to develop potential first-in-class melanocortin receptor targeted treatment for patients with retinal diseases

August 18, 2025

Palatin Announces 1-for-50 Reverse Stock Split

August 8, 2025

Palatin Announces Positive Preclinical Efficacy Data for Oral MC4R Agonist PL7737 in Animal Model of Obesity

July 15, 2025

Palatin Reports Fiscal Year 2025 Third Quarter Results and Business Update

May 14, 2025

Palatin Presents Promising Preclinical Data on Melanocortin Agonists for Retinopathy at ARVO 2025

May 9, 2025

Page 1 of 35

Older